FDA Panel Recommends Against MDMA-Assisted Therapy for PTSD

Experts cite insufficient evidence of effectiveness and concerns over trial integrity; FDA decision pending.

The advisory committee voted 9-2 against approving MDMA for PTSD treatment.
Concerns were raised about unblinded trials and underreported adverse events.
Lykos Therapeutics conducted the trials, which showed promising but controversial results.
Public testimonies highlighted both the potential benefits and ethical issues of the therapy.
The FDA will make the final decision by August 11.